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ABSTRACT 
Purpose: Asthma is associated with reversible airway obstruction, leucocyte infiltration, 
airways hyperresponsiveness (AHR) and airways remodelling. Fluid accumulation causes 
pulmonary oedema contributing to airways obstruction. We examined the temporal 
relationship between the late asthmatic response (LAR) following allergen challenge of 
sensitised guinea-pigs and pulmonary oedema measured by magnetic resonance imaging 
(MRI). 
Materials and Methods: Ovalbumin (OVA) sensitised guinea-pigs received either a 
single OVA inhalation (acute) or nine OVA inhalations at 48 h intervals (chronic). 
Airways obstruction was measured as specific airways conductance (sGaw) by whole 
body plethysmography. AHR to inhaled histamine and bronchoalveolar lavage for 
leucocyte counts were measured 24 h after a single or the final chronic ovalbumin 
challenges. MRI was performed at intervals after OVA challenge and high intensity 
oedemic signals quantified. 
Results: Ovalbumin caused early bronchoconstriction, followed at 7 h by a LAR and at 
24 h AHR and leucocyte influx.  The bright intensity MRI oedema signal, peaking at 7 h, 
was significantly (P<0.05) greater after chronic (9.0±0.7x103 mm3) than acute OVA 
(7.6±0.2x103 mm3). Dexamethasone treatment before acute OVA abolished the AHR and 
LAR and significantly reduced eosinophils and the bright intensity MRI oedema from 
9.1±1.0 to 6.4±0.3x103 mm3. 
Conclusion: We show a temporal relationship between oedema and the LAR and their 
parallel reduction, along with eosinophils and AHR, by dexamethasone. This suggests a 
close causative association between pulmonary oedema and impaired airways function.  
 
Key words: Airways hyperresponsiveness, dexamethasone, guinea-pig, magnetic 
resonance imaging (MRI), oedema, ovalbumin 
 
 
INTRODUCTION 
 
Asthma is a chronic inflammatory disease characterized by airway inflammation, airway 
hyperresponsiveness (AHR), reversible airway obstruction and airway remodelling [1]. 
Remodelling of the airways wall microvasculature through angiogenesis can contribute to 
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airways oedema [2]. Pulmonary oedema is defined as an abnormal accumulation of fluid 
in the extravascular compartments of the lung [3]. It can be caused by an increase in 
either the permeability or hydrostatic pressure within the lung blood vessels resulting in 
fluid escaping the microvasculature and entering the surrounding tissue [4]. The plasma 
leakage leading to oedema formation together with mucus hypersecretion all contribute to 
luminal airway narrowing and therefore impair lung function [5]. The use of magnetic 
resonance imaging (MRI) could prove a useful tool in evaluating oedema formation in 
asthmatics and in pre-clinical animal models of asthma. It could also be a valuable non-
invasive methodology for determining the effects of potential asthma therapeutics on 
pulmonary oedema associated with asthmatic lungs.  
 
Dexamethasone is a systemically administered corticosteroid recommended for moderate 
to severe exacerbations of asthma [6]. Although it is an extremely potent corticosteroid, 
the side-effects associated with orally administered dexamethasone limit its use [7]. 
Despite this, dexamethasone has been commonly used in animal models of asthma and 
has been effective at reducing the late asthmatic response, airway hyperresponsiveness 
(AHR) and cellular influx associated with asthma [8].  The use of proton MRI has been 
shown to provide a non-invasive measure of inflammation/oedema in the lung and this 
has been correlated with inflammatory cell infiltrates in bronchoalveolar lavage (BAL) 
samples and lung histology [9]. Typical MR images of lung are predominantly dark in 
appearance due to the low signal associated with lung parenchyma.  Using conventional 
proton MRI it is also possible to detect any cell recruitment, accumulation of 
oedema/mucin, as well as collagen deposition within the lung due to the increase in signal 
that such aggregations produce. MRI of rat lungs has shown a good correlation between 
oedema and inflammatory cells and other inflammatory markers in BAL fluid after 
allergen challenge and inhibition of the oedema by budesonide [4, 10]. In the present 
study we apply MRI to examine whether there is a correlation between oedema and 
airways obstruction, together with inflammatory cell influx in allergen-challenged 
guinea-pigs. In particular, we also determined whether attenuation of the late asthmatic 
response (LAR) by the potent corticosteroid, dexamethasone, would be associated with 
oedema reduction.  
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MATERIALS and METHODS 
 
Animals 
Groups of six male Dunkin-Hartley guinea-pigs (Harlan, UK) weighing 150-175 g were 
sensitized and challenged with ovalbumin (OVA). The guinea-pigs either followed an 
acute protocol established by Smith & Broadley [11] or a chronic protocol [12]. Guinea-
pigs were sensitized with bilateral intraperitoneal injections of. OVA (100 µg) and 
Al(OH)3 (100 mg) on days 1 and 5. On day 15, guinea-pigs following the acute protocol 
were challenged with inhaled OVA (0.01%, 1 h) or saline. Guinea-pigs following the 
chronic protocol received a further 8 exposures of OVA at 10-fold higher concentration 
(0.1%) or saline every 48 hours. All but the last challenge was under mepyramine cover 
(30 mg/kg i.p.) to prevent fatal anaphylaxis. A summary of both protocols in provided in 
Figure 1. All procedures involving animals were ethically reviewed and carried out in 
accordance with European Directive 2010/63/EU and the GSK Policy on the Care, 
Welfare and Treatment of Animals 
 
Measurement of airways obstruction  
Whole-body plethysmography was used to determine specific airway conductance (sGaw). 
Guinea-pigs were placed in a restrainer with a neck clamp and a mask fitted over the 
snout to record airflow by means of a pneumotachograph connected to a UP1 pressure 
transducer. The restrainer was then placed into the plethysmograph and the endplate 
closed. Box pressure in the plethysmograph was measured by a UP2 pressure transducer. 
Respiratory flow and box pressure were converted into waveforms with Biopac system 
(Lectromed, UK) and specific airways conductance (sGaw) determined by 
Acqknowledge® software. Readings were taken for 5 seconds which would include an 
average of 8 breaths. Baseline values were recorded before OVA exposure, and following 
the hour-long exposure, values were recorded at 0, 15, 30, 45 and 60 minutes, then hourly 
until 12 hours with a final reading at 24 hours. In order to capture both the early and late 
asthmatic bronchoconstrictor responses, the maximum bronchoconstriction occurring 
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between 0-6 hours and between 7-12 hours were recorded and displayed as separate 
histograms next to the time course plot. 
 
Airway responsiveness 
Airway responsiveness was assessed by exposing the guinea-pigs to 1 mM histamine for 
20 seconds. This was done 24 hours before the single acute OVA exposure or the first of 
the chronic exposures and repeated 24 hours after the single or final OVA exposure. 
Readings of sGaw were taken at baseline prior to histamine exposure and at 0, 5 and 10 
minutes following the histamine exposure. 
 
Bronchoalveolar lavage 
 After the final histamine exposure, the guinea-pigs were administered a lethal dose of 
sodium pentobarbitone (Euthatal i.p. 400 mg/kg), the trachea cannulated and the lungs 
removed before lavaging one lung half with saline (1 ml/100g guinea-pig) twice. Total 
cells were counted in the pooled samples with a Neubauer haemocytometer and 
differential cell counts after Cytospin centrifugation of 100l of BAL fluid onto 
microscope slides and staining with 0.15% Leishman’s solution in methanol. 
 
Magnetic resonance imaging (MRI) 
To assess in vivo lung inflammation MRI scanning was employed.  Images were acquired 
using a Bruker 4.7 Tesla magnet with an 11.6 cm gradient insert and a 72 mm coil and 
cradle. Multislice coronal images using a gradient echo sequence was employed to 
acquire data from the entire pulmonary cavity. Field of view was 7.2cm, slice thickness, 
1.8 mm; interslice distance, 2.4 mm using: an echo time (TE) = 2.0 ms, and a repetition 
time (TR) = 150 ms, 15° flip angle,  spectral width = 50,000 Hz, 256 x128 matrix with 8 
averages (2.5min). Before the guinea-pigs were placed in the MRI scanner they were 
anaesthetised with isofluorane (1-4%) and oxygen/air as the carrier for the isofluorane, 
this was maintained throughout the whole time they were in the machine via an actively 
scavenged open face mask unit. Depth of anaesthesia was measured by the animals’ 
respiration rate which was maintained at a similar level for all animals. The guinea-pigs 
were placed in the supine position for imaging. As reproducing the position of the guinea-
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pig for each scan was important for comparison of the images, initial ~1 min scout 
images were recorded to check the positioning of the axial, coronal and sagittal views. By 
using these scans, the final field of view for the main scan was carefully positioned using 
precise boundary information such as spine positioning and distances from the apex of 
the heart.  Baseline images were captured before any challenges took place and at 15 
minutes and at 4, 7 and 24 hours subsequent to the final OVA exposure. The MRI scans 
in figures 2 and 6 show the slices captured in one scan. 
 
Lung volume and bright signal within the lung were quantified using Analyze 7.0 
software (Mayo Clinic, KS, USA). A contour encompassing the lung was drawn and 
applied to each of the 7 slices of the scan (the trachea, main bronchi and heart were not 
included within the contour).  The total volume of this lung contour was calculated.  The 
oedematous lung area was subtracted from the main image by applying a signal intensity 
threshold filter (specific to each animal) to the lung contour whereby only pixels above a 
certain predefined intensity were included in the newly defined image. Measurement of 
the volume of this new image enabled the quantification of absolute bright signal (mm3) 
for each scan.  The mean signal intensity ± SD of voxels associated with the oedematous 
lung tissue were computed by placing 6 regions of interest (ROIs) of approximately 1.2 
mm radius in various areas of homogeneous intensity within the subtracted image and 
measuring their intensity. The signal intensity was assessed for all voxels within the 
previously determined lung region (within the contour). Volumetric quantitative data 
were calculated as the number of voxels below the calculated threshold (normal lung 
tissue) and above the threshold (oedematous tissue), resulting in lung and oedematous 
volumes (as well as mean ± SEM intensity of oedematous voxels) [9]. 
   
Drug dosing 
Dexamethasone (20 mg/kg) or vehicle (saline:DMSO 50:50) were administered by 
intraperitoneal bilateral injections (0.1ml) at 24 hours and 30 minutes before the OVA 
exposure and 6 hours after the exposure in the acute experiments.  
 
Materials 
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Aluminium hydroxide, dexamethasone, dimethyl sulfoxide, histamine diphosphate, 
mepyramine maleate and ovalbumin were obtained from Sigma-Aldrich, Pool, UK. Sodium 
pentobarbitone (Euthetal) was purchased from Merial, Harlow, UK. Dexamethasone was 
dissolved in saline and DMSO (50:50). All other drugs and materials were dissolved in saline 
purchased from Baxter Healthcare, Newbury, UK. 
 
Data and statistical analysis 
Mean cell counts (± SEM) were recorded as cells/ml bronchoalveolar lavage fluid and 
mean changes in lung function (± SEM) were measured as the fall in sGaw expressed as a 
percentage of the baseline value before exposure to OVA or histamine. Mean volumes of 
bright intensity (± SEM) were recorded. Comparisons between pairs of data were made 
by Student’s paired or unpaired t-test as appropriate and between multiple groups by 
Analysis of Variance followed by a Bonferroni post-test. Significance was assumed when 
P<0.05. 
 
 
RESULTS 
 
MRI scans after acute and chronic saline or OVA 
 
Figure 2 shows sections taken from naïve, saline challenged and OVA challenged guinea-
pigs 7 hours post-exposure. The level of bright intensity (white areas) is clearly greater in 
the two sections from the acute and chronic OVA-challenged animals. The quantified 
volumes of bright intensity (Table 1) show significantly greater levels after acute OVA 
challenge than after acute saline challenge at 4 (33.3%), 7 (29.4%) and 24 hours 
(44.4%)(Fig. 3a). Chronic OVA exposures led to a significantly greater intensity than 
chronic saline exposures at baseline (32.7%), 15 minutes (42.6%), 4 hours (50.8%), 7 
hours (50.0%) and 24 hours (29.8%) following the final exposure (Fig. 3b). 
 
Figure 3c compares acute and chronic challenges with either saline or OVA. At baseline 
(i.e. before the final OVA challenge) and 15 minutes and 4 hours after the final challenge, 
chronic OVA caused a significantly greater volume of bright intensity (82.5%) than acute 
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OVA challenge . However, no significant difference was seen at the 7 hour and 25 hour 
time points. 
 
Airways obstruction after acute OVA challenge 
 
An immediate bronchoconstriction characterized by a decrease in sGaw followed the OVA 
inhalation, in the vehicle- (-59.1±5.3%) and dexamethasone- (-56.8±7.7%) treated OVA 
sensitized guinea-pigs. This resolved by 5 h (Fig. 4a). At 7 hours after OVA challenge, 
there was a second bronchoconstriction or late asthmatic response (LAR), in the vehicle-
treated guinea-pigs, which was abolished by dexamethasone treatment. The mean peak 
sGaw values for the LAR in the dexamethasone-treated group (-5.9±1.2%) were 
significantly less than after vehicle treatment (-26.3±4.8%).   
 
Histamine inhalation (1 mM, 20 seconds) before OVA challenge(s) produced no 
bronchoconstriction as sGaw did not change (+0.1±1.2%) (Fig. 4b). However, 24 h after 
the acute OVA challenge, there was a significant bronchoconstriction (-41.4±7.6%) 
immediately following the histamine challenge in vehicle-treated guinea-pigs (Fig. 4b). 
This was still significant 5 minutes after the histamine challenge (-24.5±4.6%) compared 
to the pre-OVA value (-1.0±2.1%) but resolved after 10 minutes. Dexamethasone 
treatment abolished this increased responsiveness to histamine with no significant 
difference between pre-OVA and post-OVA exposures after a histamine challenge   
 
Bronchoalveolar lavage inflammatory cells 
 
Acute OVA challenge of vehicle-treated animals caused significant increases in the total 
inflammatory cell counts and eosinophils compared with naïve animals (Fig. 5). 
Dexamethasone treatment significantly reduced the total number of BAL fluid cells 
compared to vehicle (2.9±0.2x106/ml compared to 6.2±0.6x106/ml respectively) (Fig. 5). 
Dexamethasone also reduced eosinophil number (2.0±0.05x106/ml compared to 
1.8±0.08x106/ml respectively) and lymphocyte number (0.05±0.01x106/ml compared to 
0.2±0.03x106/ml respectively). 
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Effect of dexamethasone on MRI sections 
 
Figure 6a shows a typical increase in the level of bright intensity in a single slice taken 
from a vehicle-treated guinea-pig at 7 hours after an acute OVA challenge. Figure 6b 
shows the reduced levels of bright intensity in the lungs after treatment with 
dexamethasone also at 7 hours after exposure to OVA. Dexamethasone significantly 
reduced the volume of bright intensity compared to vehicle treated guinea-pigs 7 hours 
after an OVA exposure (6.4±0.3x103 mm3 compared to 9.1±1.0x103 mm3 respectively) 
(Fig. 6c).  
 
DISCUSSION 
 
 
 
We used MR imaging in guinea-pigs to demonstrate pulmonary oedema as measured by 
an increase in lung bright intensity following OVA challenge of OVA-sensitised animals. 
In the acute OVA challenged group a significant difference from the saline challenged 
was observed at 4 hours with the maximum levels of oedema observed at 7 hours. At 24 
hours the levels of oedema were reduced suggesting some recovery. However, levels 
were still greater than baseline, suggesting recovery takes longer than 24 hours. 
 
Several previous studies have also used MR imaging on animal models of asthma in rats 
[4, 10] and mice [9]. Lipopolysaccharide-induced pulmonary oedema has been previously 
measured by MRI and has shown to be inhibited following a prophylactic dose of 
dexamethasone [13]. Ovalbumin (OVA) sensitised and challenged Brown-Norway rats 
showed increased oedema 6 hours after challenge. This oedema increased to a maximum 
at 48 hours and then decreased at 96 hours [10]. This study also showed that oedema 
peaked 6 hours after repeated challenges and then steadily decreased. However, the peak 
level of oedema decreased after each challenge suggesting that tolerance could have 
occurred. Further studies in Brown-Norway rats showed a correlation between MRI high 
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intensity oedemic signals and BAL eosinophil number following OVA sensitisation and 
challenge [10]. In OVA sensitised mice an increase in oedema was observed 24 hours 
after the second OVA challenge [5].  However, like in the rats, the MRI high intensity 
oedemic signal became less intense after each challenge. By using hyperpolarized noble 
gases, such as 3He and 129Xe, in conjunction with MRI, it is possible to exploit the 
inherent low signal intensity of the lung to produce high intensity signal that reports on 
ventilation and function of the lung. Such techniques have been employed in mice models 
of lung injury [14] and this technique may complement the standard MRI techniques used 
here.   
 
A somewhat unexpected finding in the present study was the presence of some oedema in 
the saline challenged group. This is probably due to the high fluid environment under 
which the guinea-pigs were exposed. The fact that maximum levels of oedema were 
observed at 7 hours which coincides with the peak of the LAR suggests that oedema 
makes a significant contribution to the LAR. But since oedema persists beyond the 
measurable airway function changes, it is possible that the changes in sGaw are only seen 
when oedema reaches a threshold level. 
 
The chronic OVA challenged group show significantly greater levels of oedema at all 
time points compared to saline challenge. The fact that there is an underlying level of 
oedema at the baseline time-point is likely to be a consequence of persistence of the 
oedema from the previous repeated challenges with OVA. Despite the high levels of 
basal oedema in the chronic OVA challenged group, the levels of oedema still increased 
to a maximum level 7 hours after the final challenge. In our previous studies with this 
chronic OVA model, we have shown that the final challenge with OVA also produces a 
LAR peaking at 7 hours [12]. Thus, the correlation between oedema and the LAR appears 
to hold true in the chronic model as well. The increase in oedema from baseline levels to 
7 hours is not as pronounced as was observed in the acute OVA group suggesting that a 
maximal level of oedema was reached, possibly a result of the remodelling that also 
occurs in the airways of this chronic model [12]. When the levels of oedema were 
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compared between acute and chronic challenges a significantly greater baseline level was 
observed in the chronic OVA challenged group compared to acute OVA challenge.  
   
Dexamethasone significantly inhibited the late asthmatic response, the AHR to inhaled 
histamine and the influx of inflammatory cells, confirming the anti-inflammatory nature 
of this corticosteroid. Dexamethasone is an orally administered corticosteroid used to 
treat severe asthma and its exacerbations [15] and its effectiveness against the late 
asthmatic inflammation was therefore expected. Eosinophils play a major role in causing 
the lung inflammation observed in asthma with the number of eosinophils correlating 
with the severity of asthma [16]. A large influx of eosinophils was observed following an 
OVA challenge in the vehicle-treated group compared to naïve guinea-pigs and this was 
significantly reduced by dexamethasone. Pre-treating guinea-pigs with dexamethasone 
also caused a significant reduction in the levels of oedema at 7 hours compared to vehicle 
treatment. Despite this, levels of oedema were still higher than naïve guinea pigs 
suggesting that complete eradication of pulmonary oedema is not required for late phase 
attenuation. This also confirms that a threshold level of oedema is required before 
changes in sGaw can be detected. 
 
Previous data have shown that OVA sensitization and challenge in guinea-pigs causes 
early and late asthmatic responses, AHR, cellular influx after acute challenge [11, 12] and 
additionally airway remodeling after chronic exposures [12, 17]. This study confirms that 
the OVA sensitization and challenge also induces pulmonary oedema which appears to 
correlate with the LAR. This LAR oedema can be significantly inhibited by corticosteroid 
treatment. Our result confirms a previous study in rats where antigen-induced LAR was 
associated with pulmonary oedema [18]. However, this appears to be the first study to 
show pulmonary oedema correlating with the LAR, both of which can be attenuated by 
corticosteroid treatment in OVA challenged guinea-pigs.  We used OVA in the present 
study to produce clean allergen-induced inflammation rather than house dust mite extract 
which is often used now in mice but may suffer the disadvantage of having additional 
mechanisms of action [19] 
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Eosinophils, which play a key role in asthma, have been suggested to contribute towards 
oedema [10]. Since eosinophils have been implicated in the LAR, this could explain the 
correlation between oedema and the LAR. Oedema has been associated with inducing 
hyperresponsiveness [20] as have eosinophils [21], further corroborating the role of 
eosinophils in causing pulmonary oedema. Levels of eosinophils found in BAL fluid 
correlate with the levels of MRI high intensity oedemic signal. In rats pre-treated with 
budesonide a reduced level of eosinophils and MRI signal has been observed [10]. It is 
likely that dexamethasone has the same mechanism as budesonide, in that inhibition of 
eosinophil influx decreases levels of oedema, LAR and AHR. Dexamethasone treatment 
did not completely eliminate the level of oedema, which still peaked at 7 hours. Since the 
eosinophils were also not reduced to levels seen in naïve animals by dexamethasone, this 
suggests that low levels of activated eosinophils can still cause oedema in the lungs. 
 
Although oedema has been shown to develop in the lungs of asthmatics [22, 23], in some 
animal models the levels of oedema appear to reduce after multiple challenges [5, 10]. 
The Tigani study implies that the reduced leakage is a result of increased vessel wall 
thickness following repeated allergen challenge. However, the formation of new blood 
vessels, angiogenesis, is associated with chronic asthma [24] suggesting that there should 
be more plasma leakage from an increased number of blood vessels and therefore more 
oedema. Indeed, in our study, the level of oedema was consistently greater after chronic 
OVA exposure than after acute challenge.  It is likely that the decreased levels of oedema 
in the previous studies of Tigani et al. [10] and Ble et al. [5] are a result of allergen 
tolerance. Oral tolerance in sensitized animals has been shown to decrease oedema 
formation [25]. 
 
Conclusions 
 
The fact that oedema was observed in the chronic OVA model, as it is in asthmatics, 
suggests that this is an extremely useful pre-clinical model of asthma. The use of MRI for 
assessing the effect of anti-inflammatory drugs could prove to be a useful tool not only in 
animal models but also clinically. It provides a non-invasive way of accurately assessing 
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the levels of oedema in the lung, a factor which appears to be highly correlated with 
levels of pulmonary inflammation. One issue of using MRI is that images can be distorted 
because of the guinea-pig’s spontaneous breathing, however, taking repetitive 
measurements allows for a better MRI high intensity oedemic signal and therefore a 
clearer image and overcomes this issue. 
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Figure Legends 
FIGURE 1. Protocols for acute and chronic ovalbumin challenges of guinea-pigs and 
MRI scanning. 
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FIGURE 2. Representative MRI scans from groups of six animals obtained through the 
chest of a naïve guinea-pig or guinea-pigs exposed to acute or chronic inhalation 
challenges with ovalbumin or saline. Images were taken 7 h after the challenge and show 
the highest bright intensity after chronic ovalbumin exposures. 
 
FIGURE 3. The mean (± SEM) volume of bright intensity in MRI scans of naïve or 
OVA-sensitized guinea-pigs exposed to OVA or saline. a. Comparison of acute saline 
and OVA. * significantly different from acute saline (P<0.05, n=6). b. Comparison of 
chronic saline and OVA. * significantly different from chronic saline (P<0.05, n=6). c. 
Comparison of acute and chronic saline or acute and chronic OVA. # significant 
difference between acute and chronic OVA challenge. The dashed line indicates the basal 
level of bright intensity in tissues such as the heart.  
 
FIGURE 4. Airways function responses of OVA-sensitized guinea-pigs. a. Responses 
following a single acute OVA challenge. b. Responses immediately after histamine 
challenges 24 h before and 24 h after acute OVA challenge. Responses are plotted as the 
mean (±SEM) change in sGaw expressed as a percentage of the baseline value 
immediately before the OVA or histamine challenge. Guinea-pigs were either treated 
with dexamethasone (20 mg/kg i.p.) or its vehicle (DMSO:saline, 50:50) 24 h and half an 
hour before and 6 h after OVA challenge. In a, the bar charts on the right are the mean (± 
SEM) peak changes in sGaw occuring between 0-6 and 7-12 h and at 24 h after OVA 
challenge. In a, significant differences between dexamethasone and vehicle treated 
guinea-pigs are represented by * and ^, and in b, significant differences between 
responses to histamine before and after OVA challenge are indicated by * (P<0.05, n=6, 
Student’s two-tailed t-test). 
 
FIGURE 5. Total leucocytes, macrophages, eosinophils, lynphocytes and neutrophils in 
bronchoalveolar lavage fluid of naïve (non-sensitized) guinea-pigs and 24 h after an acute 
OVA challenge of guinea-pigs treated with dexamethasone (20 mg/kg i.p.) or its vehicle 
(DMSO:saline, 50:50) 24 h and half an hour before and 6 h after OVA challenge. Values 
are the mean (± SEM) numbers of cells/ml. * significantly different from naïve animals 
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and ^ significantly different from vehicle treated guinea-pigs by Analysis of Variance 
followed by Bonferroni post-test (P<0.05, n=6).  
 
FIGURE 6. Representative MRI scans obtained through the chest of sensitized guinea-
pigs exposed to acute inhalation challenges with ovalbumin and treated with a. vehicle or 
b. dexamethasone. Images were taken 7 h after the challenge and show reduced bright 
intensity after dexamethasone treatment. c. Mean volume of bright intensity (± SEM) in 
naïve and OVA sensitized acute OVA challenged guinea-pigs treated with 
dexamethasone (20 mg/kg i.p.) or its vehicle (DMSO:saline, 50:50) 24 h and half an hour 
before and 6 h after OVA challenge. The dashed line highlights the basal level of bright 
intensity caused by tissues such as the heart. * significantly different from vehicle treated 
guinea-pigs by Student’s two-tailed t-test (P<0.05, n=6). 
 
